Several other equities research analysts have also weighed in on the company. Wells Fargo & Co reiterated a buy rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 14th. Piper Jaffray Companies lowered Jazz Pharmaceuticals from an overweight rating to a neutral rating and lowered their price objective for the company from $205.00 to $142.00 in a research note on Wednesday, August 21st. Sanford C. Bernstein reiterated a market perform rating and issued a $150.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, October 14th. Oppenheimer set a $176.00 price objective on Jazz Pharmaceuticals and gave the company a buy rating in a research note on Thursday, September 26th. Finally, TheStreet lowered Jazz Pharmaceuticals from a b- rating to a c+ rating in a research note on Friday, October 18th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of $165.71.
JAZZ traded up $4.82 during trading on Wednesday, reaching $138.64. 543,000 shares of the stock traded hands, compared to its average volume of 470,552. Jazz Pharmaceuticals has a fifty-two week low of $113.52 and a fifty-two week high of $154.44. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.89 and a quick ratio of 3.71. The stock has a market cap of $7.57 billion, a price-to-earnings ratio of 11.33, a price-to-earnings-growth ratio of 1.05 and a beta of 1.09. The stock’s 50-day simple moving average is $125.17 and its two-hundred day simple moving average is $131.83.
In other news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the transaction, the chief executive officer now directly owns 311,855 shares of the company’s stock, valued at approximately $40,541,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.30% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC boosted its holdings in shares of Jazz Pharmaceuticals by 56.3% in the 2nd quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 72 shares in the last quarter. Machina Capital S.A.S. acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $29,000. Captrust Financial Advisors boosted its holdings in shares of Jazz Pharmaceuticals by 120.0% in the 2nd quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 120 shares in the last quarter. MUFG Americas Holdings Corp acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $29,000. Finally, Stonebridge Capital Advisors LLC acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $37,000. 87.74% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: Options Trading
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.